Oruka Therapeutics, Inc. Common Stock

ORKANASDAQ • USD
99.26 USD
↗ 0.02 (0.02%)🟢PRE MARKET (AS OF 03:45 AM EST)
🟢Market: OPEN

Shares of Oruka Therapeutics, Inc. Common Stock (ORKA) are trading at $99.26. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place ORKA at a fair price relative to peers.

Technical & fundamental data as of Nov 16, 2026.

Open?N/A
High?N/A
Low?N/A
Prev. Close?$99.24
Volume?0
Avg. Volume?988.8K
Bid / Ask
Bid?$85.61 × 100
Ask?$113.31 × 100
Spread?$27.70
Midpoint?$99.46
Valuation & Ratios
Market Cap?6.7B
Shares Out?67.8M
Float?53.1M
Float %?80.2%
P/E Ratio?N/A
P/B Ratio?5.62
EPS?-$2.01
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Employees
68
Market Cap
7.1B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2024-09-03
Address
855 OAK GROVE AVE.
MENLO PARK, CA 94025
Phone: 650-606-7910
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
49
Piotroski F-Score?0/9Weak
Altman Z-Score?119.26Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.18%High
Short Interest?6.5M
Days to Cover?7.1
Free Float53.1M
Avg Daily Volume915.1K
Settlement Date2026-10-30
Financial Health
Current Ratio?29.62Strong
Quick Ratio?29.62Strong
Cash Ratio?6.03Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
33
5.62FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-35.7CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
9
-11.4%WEAK▾
ROA?
S&P
3
-11.1%WEAK▾
Cash Flow & Enterprise
FCF?$-123862000
Enterprise Value?$6.5B
Fundamentals ratios updated end of day